Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) insider Jones W. Bryan purchased 4,700 shares of Sucampo Pharmaceuticals stock in a transaction that occurred on Friday, August 4th. The stock was acquired at an average price of $10.60 per share, for a total transaction of $49,820.00. Following the transaction, the insider now directly owns 4,700 shares of the company’s stock, valued at approximately $49,820. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at 10.45 on Tuesday. The company’s market cap is $482.73 million. The firm’s 50-day moving average is $10.58 and its 200-day moving average is $10.73. Sucampo Pharmaceuticals, Inc. has a 52-week low of $9.30 and a 52-week high of $17.55.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The business had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. During the same period last year, the company earned $0.24 EPS. The company’s revenue for the quarter was up 15.3% on a year-over-year basis. On average, equities research analysts anticipate that Sucampo Pharmaceuticals, Inc. will post $1.02 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Insider Jones W. Bryan Acquires 4,700 Shares of Stock” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/08/sucampo-pharmaceuticals-inc-scmp-insider-jones-w-bryan-acquires-4700-shares-of-stock.html.

Several hedge funds have recently modified their holdings of the company. Louisiana State Employees Retirement System bought a new stake in shares of Sucampo Pharmaceuticals during the first quarter worth about $111,000. Karp Capital Management Corp bought a new stake in shares of Sucampo Pharmaceuticals during the first quarter worth about $119,000. First Citizens Bank & Trust Co. bought a new stake in shares of Sucampo Pharmaceuticals during the second quarter worth about $116,000. SG Americas Securities LLC increased its stake in shares of Sucampo Pharmaceuticals by 5.6% in the second quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 631 shares during the period. Finally, Capstone Asset Management Co. bought a new stake in shares of Sucampo Pharmaceuticals during the first quarter worth about $133,000. 58.20% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts recently weighed in on the stock. TheStreet cut shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Maxim Group set a $23.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. BidaskClub cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Jefferies Group LLC reduced their price target on shares of Sucampo Pharmaceuticals from $13.00 to $11.00 and set a “hold” rating on the stock in a research report on Thursday, May 4th. Finally, Roth Capital set a $30.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $17.63.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.